Cd9 as a new biomarker for diagnosing or predicting risk of glomerulonephritis

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and 1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritis. Scientific Publication(s): Nat Commun, 2019 Jul 24, Lazareth H. el al., The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression, doi: 10.1038/s41467-019-11013-2

Keywords: IHC, Immunoassay, Diagnostic, Risk Prediction in Glomerulonephritis
Patent Application number: EP19 305 721.3
Publications:
Nat Commun. 2019 Jul 24;10(1):3303. doi: 10.1038/s41467-019-11013-2.

Reference:

BIO19208-D1

Business Developper
contact
Sylvestre CHEA
Sylvestre CHEA
Business Development Manager
Patent filling date: 2019-06-04

You might also be interested in